Form 8-K - Current report:
SEC Accession No. 0001104659-25-050226
Filing Date
2025-05-19
Accepted
2025-05-19 07:34:35
Documents
12
Period of Report
2025-05-16
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2515521d1_8k.htm   iXBRL 8-K 31933
  Complete submission text file 0001104659-25-050226.txt   198387

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nvax-20250516.xsd EX-101.SCH 3011
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvax-20250516_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvax-20250516_pre.xml EX-101.PRE 22356
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2515521d1_8k_htm.xml XML 3558
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 25961500
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)